Sanofi (Mexico) Performance
| SNYN Stock | MXN 964.00 6.00 0.63% |
The entity has a beta of -0.25, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Sanofi are expected to decrease at a much lower rate. During the bear market, Sanofi is likely to outperform the market. At this point, Sanofi has a negative expected return of -0.21%. Please make sure to validate Sanofi's total risk alpha, potential upside, kurtosis, as well as the relationship between the treynor ratio and skewness , to decide if Sanofi performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Sanofi has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 10.1 B |
Sanofi |
Sanofi Relative Risk vs. Return Landscape
If you would invest 109,639 in Sanofi on September 24, 2024 and sell it today you would lose (13,839) from holding Sanofi or give up 12.62% of portfolio value over 90 days. Sanofi is generating negative expected returns and assumes 1.4404% volatility on return distribution over the 90 days horizon. Simply put, 12% of stocks are less volatile than Sanofi, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Sanofi Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sanofi's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sanofi, and traders can use it to determine the average amount a Sanofi's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1438
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SNYN |
Estimated Market Risk
| 1.44 actual daily | 12 88% of assets are more volatile |
Expected Return
| -0.21 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sanofi is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sanofi by adding Sanofi to a well-diversified portfolio.
Sanofi Fundamentals Growth
Sanofi Stock prices reflect investors' perceptions of the future prospects and financial health of Sanofi, and Sanofi fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sanofi Stock performance.
| Return On Equity | 0.0959 | |||
| Return On Asset | 0.0607 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 2.69 T | |||
| Shares Outstanding | 2.47 B | |||
| Price To Earning | 414.95 X | |||
| Price To Book | 1.61 X | |||
| Price To Sales | 52.71 X | |||
| Revenue | 45.39 B | |||
| EBITDA | 10.76 B | |||
| Cash And Equivalents | 8.73 B | |||
| Cash Per Share | 3.50 X | |||
| Total Debt | 14.86 B | |||
| Debt To Equity | 47.20 % | |||
| Book Value Per Share | 29.16 X | |||
| Cash Flow From Operations | 10.52 B | |||
| Earnings Per Share | 56.31 X | |||
| Total Asset | 124.58 B | |||
About Sanofi Performance
Evaluating Sanofi's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Sanofi has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sanofi has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1 and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody for multiple sclerosis. Sanofi was founded in 1973 and is headquartered in Paris, France. SANOFI is traded on Mexico Stock Exchange in Mexico.Things to note about Sanofi performance evaluation
Checking the ongoing alerts about Sanofi for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sanofi help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sanofi generated a negative expected return over the last 90 days |
- Analyzing Sanofi's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sanofi's stock is overvalued or undervalued compared to its peers.
- Examining Sanofi's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sanofi's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sanofi's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sanofi's stock. These opinions can provide insight into Sanofi's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sanofi Stock Analysis
When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.